Trevi Therapeutics, Inc.
TRVIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary. The $2.71B market capitalization puts TRVI squarely in mid-cap range for its industry. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Market Cap
$2.71B
Beta
1.00
P/E (TTM)
—
P/E (Fwd)
-34.19
EPS (TTM)
$-0.35
EPS (Fwd)
$-0.56
ROE
-33.6%
ROA
-23.0%
Cash
$171.8M
Total Debt
$682,000
Free CF
-$28.5M
52W Change
178.0%
Annual Financials
Cash vs Debt
Trevi Therapeutics, Inc. holds $171.8M in cash against $682K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$28.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -33.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Trevi Therapeutics, Inc.'s trajectory.